{"pmid":32356577,"title":"Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.","text":["Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.","During COVID-19 outbreak there are discordant opinion towards the impact on biologics in psoriatic patients. Thus we performed a single center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and 5 hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to be symptomatic for COVID-19 (OR 3.43 [95%CI 2.25-5.73], P < 0.0001), to be self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], P < 0.0001) and hospitalized (OR 3.59 [95%CI 1.49-8.63], P = 0.0044) however not increased risk of ICU admission or death were found. PsO Patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm. This article is protected by copyright. All rights reserved.","Dermatol Ther","Damiani, Giovanni","Pacifico, Alessia","Bragazzi, Nicola L","Malagoli, Piergiorgio","32356577"],"abstract":["During COVID-19 outbreak there are discordant opinion towards the impact on biologics in psoriatic patients. Thus we performed a single center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and 5 hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to be symptomatic for COVID-19 (OR 3.43 [95%CI 2.25-5.73], P < 0.0001), to be self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], P < 0.0001) and hospitalized (OR 3.59 [95%CI 1.49-8.63], P = 0.0044) however not increased risk of ICU admission or death were found. PsO Patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Damiani, Giovanni","Pacifico, Alessia","Bragazzi, Nicola L","Malagoli, Piergiorgio"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356577","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/dth.13475","keywords":["bilateral interstitial pneumonia","biologics","covid-19","pandemic","psoriasis","psoriatic arthritis","sars-cov-2"],"locations":["Lombardia","Italian","Lombardy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138495229362176,"score":9.490897,"similar":[{"pmid":32415727,"title":"COVID-19 knowledge prevents biologics discontinuation: data from an Italian multi-center survey during RED-ZONE declaration.","text":["COVID-19 knowledge prevents biologics discontinuation: data from an Italian multi-center survey during RED-ZONE declaration.","BACKGROUND: SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. OBJECTIVE: To assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. METHODS: We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics - 51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to i) epidemiology, ii) pathogenesis, iii) clinical symptoms, iv) preventive measures and v) attitudes. Patients data and questionnaires were collected. RESULTS: Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients(p=0.001) with higher scholarity level(p=0.005) displayed higher knowledge of COVID-19. Patients with lower DLQI(p=0.006), longer disease duration(p=0.051) and lower scholarity(p=0.007) have thought to discontinue/modify autonomously their biologic therapy.At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation versus discontinuation and modification versus no modification, respectively. CONCLUSIONS: Dermatologists should promote COVID-19 to prevent biologics disruption. This article is protected by copyright. All rights reserved.","Dermatol Ther","Bragazzi, Nicola Luigi","Ricco, Matteo","Pacifico, Alessia","Malagoli, Piergiorgio","Kridin, Khalaf","Pigatto, Paolo","Damiani, Giovanni","32415727"],"abstract":["BACKGROUND: SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. OBJECTIVE: To assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. METHODS: We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics - 51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to i) epidemiology, ii) pathogenesis, iii) clinical symptoms, iv) preventive measures and v) attitudes. Patients data and questionnaires were collected. RESULTS: Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients(p=0.001) with higher scholarity level(p=0.005) displayed higher knowledge of COVID-19. Patients with lower DLQI(p=0.006), longer disease duration(p=0.051) and lower scholarity(p=0.007) have thought to discontinue/modify autonomously their biologic therapy.At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation versus discontinuation and modification versus no modification, respectively. CONCLUSIONS: Dermatologists should promote COVID-19 to prevent biologics disruption. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Bragazzi, Nicola Luigi","Ricco, Matteo","Pacifico, Alessia","Malagoli, Piergiorgio","Kridin, Khalaf","Pigatto, Paolo","Damiani, Giovanni"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415727","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/dth.13508","keywords":["atopic dermatitis","biologics","covid-19","covid-19 questionnaire","hidradenitis suppurativa","psoriasis","sars-cov-2"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666991242692526081,"score":405.8697},{"pmid":32466199,"title":"Prioritizing and Analyzing the Role of Climate and Urban Parameters in the Confirmed Cases of COVID-19 Based on Artificial Intelligence Applications.","text":["Prioritizing and Analyzing the Role of Climate and Urban Parameters in the Confirmed Cases of COVID-19 Based on Artificial Intelligence Applications.","Nowadays, an infectious disease outbreak is considered one of the most destructive effects in the sustainable development process. The outbreak of new coronavirus (COVID-19) as an infectious disease showed that it has undesirable social, environmental, and economic impacts, and leads to serious challenges and threats. Additionally, investigating the prioritization parameters is of vital importance to reducing the negative impacts of this global crisis. Hence, the main aim of this study is to prioritize and analyze the role of certain environmental parameters. For this purpose, four cities in Italy were selected as a case study and some notable climate parameters-such as daily average temperature, relative humidity, wind speed-and an urban parameter, population density, were considered as input data set, with confirmed cases of COVID-19 being the output dataset. In this paper, two artificial intelligence techniques, including an artificial neural network (ANN) based on particle swarm optimization (PSO) algorithm and differential evolution (DE) algorithm, were used for prioritizing climate and urban parameters. The analysis is based on the feature selection process and then the obtained results from the proposed models compared to select the best one. Finally, the difference in cost function was about 0.0001 between the performances of the two models, hence, the two methods were not different in cost function, however, ANN-PSO was found to be better, because it reached to the desired precision level in lesser iterations than ANN-DE. In addition, the priority of two variables, urban parameter, and relative humidity, were the highest to predict the confirmed cases of COVID-19.","Int J Environ Res Public Health","Shaffiee Haghshenas, Sina","Pirouz, Behrouz","Shaffiee Haghshenas, Sami","Pirouz, Behzad","Piro, Patrizia","Na, Kyoung-Sae","Cho, Seo-Eun","Geem, Zong Woo","32466199"],"abstract":["Nowadays, an infectious disease outbreak is considered one of the most destructive effects in the sustainable development process. The outbreak of new coronavirus (COVID-19) as an infectious disease showed that it has undesirable social, environmental, and economic impacts, and leads to serious challenges and threats. Additionally, investigating the prioritization parameters is of vital importance to reducing the negative impacts of this global crisis. Hence, the main aim of this study is to prioritize and analyze the role of certain environmental parameters. For this purpose, four cities in Italy were selected as a case study and some notable climate parameters-such as daily average temperature, relative humidity, wind speed-and an urban parameter, population density, were considered as input data set, with confirmed cases of COVID-19 being the output dataset. In this paper, two artificial intelligence techniques, including an artificial neural network (ANN) based on particle swarm optimization (PSO) algorithm and differential evolution (DE) algorithm, were used for prioritizing climate and urban parameters. The analysis is based on the feature selection process and then the obtained results from the proposed models compared to select the best one. Finally, the difference in cost function was about 0.0001 between the performances of the two models, hence, the two methods were not different in cost function, however, ANN-PSO was found to be better, because it reached to the desired precision level in lesser iterations than ANN-DE. In addition, the priority of two variables, urban parameter, and relative humidity, were the highest to predict the confirmed cases of COVID-19."],"journal":"Int J Environ Res Public Health","authors":["Shaffiee Haghshenas, Sina","Pirouz, Behrouz","Shaffiee Haghshenas, Sami","Pirouz, Behzad","Piro, Patrizia","Na, Kyoung-Sae","Cho, Seo-Eun","Geem, Zong Woo"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32466199","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijerph17103730","keywords":["covid-19","de","pso","artificial intelligence","feature selection","sustainable development"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1668167110059098112,"score":290.97147},{"pmid":32300516,"pmcid":"PMC7160052","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32300516"],"abstract":["With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300516","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13555-020-00377-9","keywords":["biologics","covid-19","coronavirus","infection","pandemic","psoriasis","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666138494813077506,"score":271.5162},{"pmid":32379913,"title":"Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.","text":["Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.","Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19.","J Eur Acad Dermatol Venereol","Conti, A","Lasagni, C","Bigi, L","Pellacani, G","32379913"],"abstract":["Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2). We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19."],"journal":"J Eur Acad Dermatol Venereol","authors":["Conti, A","Lasagni, C","Bigi, L","Pellacani, G"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379913","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jdv.16587","keywords":["sars-cov-2","covid-19","psoriasis; biologic","therapies"],"topics":["Case Report"],"weight":1,"_version_":1666597097303965696,"score":267.67255},{"pmid":32443640,"title":"SEIR Modeling of the Italian Epidemic of SARS-CoV-2 Using Computational Swarm Intelligence.","text":["SEIR Modeling of the Italian Epidemic of SARS-CoV-2 Using Computational Swarm Intelligence.","We applied a generalized SEIR epidemiological model to the recent SARS-CoV-2 outbreak in the world, with a focus on Italy and its Lombardy, Piedmont, and Veneto regions. We focused on the application of a stochastic approach in fitting the model parameters using a Particle Swarm Optimization (PSO) solver, to improve the reliability of predictions in the medium term (30 days). We analyzed the official data and the predicted evolution of the epidemic in the Italian regions, and we compared the results with the data and predictions of Spain and South Korea. We linked the model equations to the changes in people's mobility, with reference to Google's COVID-19 Community Mobility Reports. We discussed the effectiveness of policies taken by different regions and countries and how they have an impact on past and future infection scenarios.","Int J Environ Res Public Health","Godio, Alberto","Pace, Francesca","Vergnano, Andrea","32443640"],"abstract":["We applied a generalized SEIR epidemiological model to the recent SARS-CoV-2 outbreak in the world, with a focus on Italy and its Lombardy, Piedmont, and Veneto regions. We focused on the application of a stochastic approach in fitting the model parameters using a Particle Swarm Optimization (PSO) solver, to improve the reliability of predictions in the medium term (30 days). We analyzed the official data and the predicted evolution of the epidemic in the Italian regions, and we compared the results with the data and predictions of Spain and South Korea. We linked the model equations to the changes in people's mobility, with reference to Google's COVID-19 Community Mobility Reports. We discussed the effectiveness of policies taken by different regions and countries and how they have an impact on past and future infection scenarios."],"journal":"Int J Environ Res Public Health","authors":["Godio, Alberto","Pace, Francesca","Vergnano, Andrea"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32443640","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/ijerph17103535","keywords":["covid-19","italy","sars-cov-2","seir modeling","stochastic modeling","swarm intelligence"],"locations":["Italy","Lombardy","Piedmont","Veneto","Italian","Spain","South Korea"],"countries":["Korea, Republic of","Italy","Spain"],"countries_codes":["KOR|Korea, Republic of","ITA|Italy","ESP|Spain"],"topics":["Prevention","Epidemic Forecasting"],"weight":1,"_version_":1667600475785003008,"score":263.44467}]}